UPDATE: Â See October 2010 Report #S180, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015.
The current $9.1 billion global market for medical/surgical sealants, glues and wound closure is growing at an accelerated rate approaching double digit figures, with specific product segments within it growing at over 15% annually. The market potential for the future utilization of these products is expanding as a result of their progressive adoption by multiple clinician types for multiple uses (sealing, hemostasis and even anti-adhesion) and their (more) routine use in surgical and other clinical practice, demographic forces influencing potential caseload and with the changing regulatory demands for this diverse set of products.
The most well established segment of sutures, clips and staples is on the verge of being eclipsed by the volume of sales in sealants and glues, which already comprise an aggregate annual market in excess of $3 billion worldwide.
From 2010 forward, acceleration in the market growth of these products arises from the trends in product adoption, trends and forces in demographic, and the introduction of Â new products and product formulations that satisfy growing clinical demand.. There remains a a near-term potential for these products to be used in excess of 100 million procedures worldwide. Growth in utilization will also exceed double-digit annual rates for new products and for established products in geographic markets that have yet to be fully tapped.
Variable Rapid Evaluation Delayed Evaluation Expense Low cost if short follow-up, (e.g., cuts and grazes) and low-cost procedure High cost if long-term follow-up required, (e.g., ligament repair) and high cost procedure Follow-up period Some procedures require short follow-up periods (e.g., hemostasis endpoints and use of cyanoacrylate on cuts) Some procedures require at least two years follow-up (e.g., musculoskeletal sports injuries) Surgical setting Community care (lacerations) Theater (surgery) Doctor's surgery (accidents) Critical care (e.g., burns) Technology Some devices and developments have predicate devices which allow more rapid approval. Autologous products are also relatively quick to develop New biologicals, complex mixtures of biomaterials, and new chemical entities require extensive validation and testing Device for delivery Can accelerate clinical approval and improve clinical efficacy Can complicate clinical development if both device and product are new
Source: MedMarket Diligence, LLC; Report #S175, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Market, 2009-2013”.